摘要
目的建立LC-MS/MS同时测定人血浆中阿莫西林/氨溴索浓度。方法以Lichrospher C18(4.6mm×150mm,5μm)为色谱柱,流动相为甲醇溶液(含0.2%甲酸)和水溶液(含0.2%甲酸),采用梯度洗脱进行分析,流速为1.0mL·min-1,柱温为30℃。血浆样品经甲醇沉淀后进样,采用多反应监测(MRM)方式对样品进行测定。结果血浆中阿莫西林线性范围为5～20000μg·L-1,氨溴索线性范围为1～200μg·L-1;批间和批内精密度RSD均小于9%;方法的准确度为(100±7)%;最低定量限浓度(LLOQ)阿莫西林为5μg·L-1,氨溴索为1μg·L-1。结论本试验建立了同时测定阿莫西林和氨溴索浓度的方法,该方法灵敏、准确、简便、快速,适用于阿莫西林/氨溴索人体药动学研究。
Abstract
OBJECTIVE To develop a LC-MS/MS method for simultaneous determination of amoxicillin and ambroxol in human plasma. METHODS The Lichrospher C18 column (4.6 mm×150 mm, 5 μm) was used. The mobile phase consisted of methanol (containing 0.2% formic acid) and 0.2% formic acid water using the gradient program pumped at a flow rate of 1.0 mL·min-1 at 30 ℃. Plasma samples were loaded after methanol precipitation and analyzed with MRM method. RESULTS Calibration curves were linear in the concentration range of 5–20 000 μg·L-1 for amoxicillin and 1–200 μg·L-1 for ambroxol. Both of the intraand interrun precisions were less than 9% and the accuracy was (100±7)%. The LLOQs of amoxicillin and ambroxol were determined as 5.0 and 1.0 μg·L-1, respectively. CONCLUSION The established method was sensitive, accurate, simple and rapid for simultaneous determination of the concentrations of amoxicillin and ambroxol, which was applicable to the clinical monitoring and pharmacokinetic studies.
关键词
阿莫西林 /
氨溴索 /
克伦特罗 /
药动学 /
高效液相色谱-质谱联用
{{custom_keyword}} /
Key words
amoxicillin /
ambroxol /
clenbuterol /
pharmacokinetics /
LC-MS/MS
{{custom_keyword}} /
陈苏宁;文爱东;丁莉坤;贾艳艳;王志睿;杭太俊.
LC-MS/MS同时测定人血浆中阿莫西林-氨溴索浓度及其药动学研究[J]. 中国药学杂志, 2009, 44(14): 1092-1096
CHEN Su-ning;WEN i-dong;DING Li-kun;JI Yn-yn;WNG Zhi-rui;HNG Ti-jun.
Simultaneous Determination of Amoxicillin/Ambroxol in Human Plasma by LC-MS/MS and Pharmacokinetic Study [J]. Chinese Pharmaceutical Journal, 2009, 44(14): 1092-1096
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] TABISH H，LEANNE M F，SHAMIM A Q，et al. Ambulatory short-course high-dose amoxicillin for treatment of severe pneum in children: a randomised equival trial [J]. Lancet，2008，371 (9606): 49-56.
[2] PETER B. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections [J]. Int J Antimicrob，2007，30(S2): 113-117.
[3] PAGANIN F，BOUVET O，CHANEZ P，et al. Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation [J]. Biopharm Drug Dispos，1995，16 (5): 393-401.
[4] WIEMEYER J C. Influence of ambroxol on the bronchopulmonary level of antibiotics [J]. Arzneim-Forsch，1981，31 (6): 974-976.
[5] HWANG M S，CHO S，CHUNG H，et al. Nondestructive determination of the ambroxol content in tablets by Raman spectroscopy [J]. J Pharm Biomed Anal，2005，38(2)：210-215.
[6] SPATOLA J，PODEROSO J J，WIEMEYER J C，et al. Influence of ambroxol on lung tissue penetration of amoxicillin [J]. Arzneim-Forsch，1987，37(8): 965-966.
[7] HOU F，ZHANG P，LIU Y，et al. Pharmacokinetics and pharmacodynemics of amoxicillin/clavulanic acid potassium in healthy volunteers [J]. Chin J Clin Pharmacol(中国临床药理学杂志)，2006，22 (1): 40-43.
[8] QI M L，WANG P，CONG R H，et al. Simultaneous determination of roxithromycin and ambroxol hydrochloride in a new tablet formation by liquid chromatography [J]. J Pharm Biomed Anal，2004，35(5): 1287-1291.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
